# US 2025/0017991 A1 · Vlp immunotherapy combined with ablation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0017991 A1
- Document ID: US20250017991A1
- Status: Published application
- Kind: A1
- Application number: 18/708,930
- Filed: 2022-11-09
- Published: 2025-01-16
- Earliest claimed: 2021-11-11
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Nicole F. Steinmetz; Isabel Newton; Nicholas Webster; Tyler Mandt; Hui Cai; Christine Boone; Mansur Ghani
- Web page: https://patentgrep.com/patent/US20250017991A1

## CPC

- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61B 18/02: by cooling, e.g. cryogenic techniques
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2770/18023: Virus like particles [VLP]
- C12N 2770/18032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein is a novel, multimodal in situ vaccination approach to treat cancer by combining ablation with administration of the naturally occurring plant virus or virus-like particle (VLP) nanoparticles such as cowpea mosaic virus (CPMV), a plant virus-based immunoadjuvant.

## Claims

### Claim 1

A method of one or more of: treating or inhibiting the growth of a tumor or cancer in a subject in need thereof comprising administration of an effective amount of a naturally occurring plant virus or an engineered virus like particle (“VLP”) and subsequent ablation of the tumor or cancer, optionally wherein the cancer is localized or metastatic and optionally wherein the naturally occurring plant virus or the engineered VLP is administered in a composition, optionally wherein the administration is systemic or local to the tumor or cancer in the subject, and optionally wherein the ablation of the tumor or cancer comprises a method selected from one or more of cryoablation, irreversible electroporation, radiofrequency ablation, or microwave ablation.

### Claim at position 2

2-3. (Canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the naturally occurring plant virus or the engineered VLP further comprises at least one toll-like receptor (“TLR”) agonist, optionally a TLR 2, 3, 4, 7, and/or 9 agonist.

### Claim 5 (depends on 4)

The method of claim 4, wherein the TLR agonist is packaged within the naturally occurring plant virus or the engineered VLP.

### Claim 6 (depends on 4)

The method of claim 4, wherein the naturally occurring plant virus or the engineered VLP binds and activates the TLR.

### Claim 7 (depends on 1)

The method of claim 1, wherein the plant virus or the engineered VLP comprises cowpea mosaic virus (CPMV), optionally wherein the CPMV is a naturally occurring CPMV.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the tumor or cancer comprises a solid tumor, optionally a cancer derived from the oropharynx, lung, thyroid, esophagus, stomach, liver, pancreas, colon, rectum, kidney, bladder, adrenal gland, breast, uterus, cervix, ovaries, prostate, testes, mesothelium, peritoneum, skin, brain, spinal cord, bone, or lymph nodes, optionally wherein the solid tumor is selected from the group of a sarcoma, a carcinoma, or a lymphoma, and optionally wherein the solid tumor is localized or metastatic, and optionally wherein the cancer is selected from hepatocellular carcinoma, non-small cell lung cancer, small cell lung cancer, or melanoma.

### Claim 10 (depends on 1)

The method of claim 1, wherein the tumor or cancer is a cancer of one or more of: the skin, central nervous system, head and neck, breast, thorax, digestive system, genitourinary system, pelvic organs, or lymphatic system.

### Claim at position 10

11-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject is an animal or a human.

### Claim 14 (depends on 1)

The method of claim 1, wherein a plurality of naturally occurring or engineered VLPs are administered to the subject, that may be the same or different from each other.

### Claim 15 (depends on 4)

The method of claim 4, wherein the TLR agonists are the same or different from each other.

### Claim 16 (depends on 1)

The method of claim 1, further comprising two or more subsequent ablations of the tumor or cancer, that optionally may comprise the same or different method of ablation.

### Claim 17 (depends on 1)

The method of claim 1, further comprising administration of an effective amount of a checkpoint inhibitor therapy to the subject, optionally wherein the checkpoint inhibitor therapy comprises an anti-PD-1 therapy.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The method of claim 1, wherein the method is administered as a first-line, second-line, third-line, fourth-line, or fifth-line therapy.

### Claim 20 (depends on 1)

The method of claim 1, wherein the treatment provides to the subject one or more of a reduction in tumor burden, increased time to or lack of tumor recurrence, complete or partial response, longer progression-free survival, longer disease-free survival, a better objective response rate, lowered toxicity or side effects, or increased overall survival, as compared to a subject who has not received the treatment.

### Claim 21

A composition comprising a naturally occurring plant virus or engineered virus like particle (“VLP”) wherein the naturally occurring plant virus or VLP further comprises a toll-like receptor (“TLR”) agonist, optionally a TLR 2, 3, 4, 7 and/or 9 agonist, and optionally a carrier, and further optionally a detectable label, optionally wherein the TLR agonist is packaged within the naturally occurring plant virus or the engineered VLP.

### Claim 22

(canceled)

### Claim 23 (depends on 21)

The composition of claim 21, wherein the naturally occurring plant virus or the engineered VLP binds and activates the TLR.

### Claim 24 (depends on 21)

The composition of claim 21, wherein the naturally occurring plant virus or the engineered VLP comprises cowpea mosaic virus (CPMV), optionally wherein the CPMV is naturally occurring CPMV.

### Claim 25

(canceled)

### Claim 26 (depends on 21)

The composition of claim 21, comprising a plurality of the naturally occurring plant virus or the engineered VLPs, optionally wherein the plurality of the naturally occurring plant virus or the engineered VLPs are the same or different, and optionally wherein the plurality of the TLR agonists are the same or different

### Claim at position 25

27-28. (canceled)

### Claim 29 (depends on 26)

The composition of claim 26, wherein the plurality of the naturally occurring plant virus and the engineered VLPs comprise different TLR agonists.

### Claim 30 (depends on 7)

The method of claim 7, wherein administration comprises injecting the CPMV into the tumor and subsequent cryoablation of the tumor.
